They had no data regarding 5-alpha reductase inhibitor use – a drug that blocks 5-alpha reductase, preventing the conversion of testosterone into dihydrotestosterone. Active surveillance has become a widely accepted management strategy for patients with low-risk prostate cancer. One popular method is the use of a DHT blocker serum, which can help inhibit the effects of DHT on your hair follicles. This article will explore DHT's role in hair loss and how a DHT blocker serum can help mitigate its effects. Among the various contributors to hair loss, dihydrotestosterone (DHT) has garnered attention as a key player. DHT exposure did not alter serum cholesterol, including circulatinglow-density lipoprotein (LDL) or high-density lipoprotein (HDL). Aside from TRT preparations, which modestly raise serum DHT concentrations and DHT/Tratios (described in Section X), there are three double-blind, placebo-controlled trials(see "Serum DHT and DHT/T Ratios Observed in Response to Testosterone Therapy in Men WithLow T") in which men have been treated with transdermal DHT gel. Cancer risk with individuals overlapping circles of subjectswith cancer were scored as 1, whereas subjects without cancer were scored as 0. The microarray data ofandrogen-regulated genes, along with confirmation by RT-PCR, showed similar levels ofexpression and no statistically significant differences between placebo and all othertreatment arms. In contrast withthese findings, Jockenhovel et al. (136) compared four TRT preparations (including oral TU treatment of 55hypogonadal men) and found a positive correlation existed with T and hematocrit andhemoglobin levels, but not DHT. DHT can serve tostimulate erythropoiesis when given in supraphysiologic dosing, despite suppressingendogenous T and estradiol (E) (54), but it is notrequired for exogenous T to exert these effects (129–131). Of note, the broader SRD5A antagonist, dutasteride, is particularly effective forthese types of investigations, as it is a potent inhibitor of both SRD5A type I and type II,whereas finasteride is a less potent inhibitor of SRD5A type I (127). The processes involved inthrombosis are complex and reflect the integrated response of pro- and antithromboticmediators as well as complex interactions of androgen and estrogen that are poorlyunderstood. There has been a long-standing concern regarding androgen use and its potentialrelationship to thrombosis, an area that remains controversial (119, 120). Further evaluation of DHT in blood vessel pathologies is merited,particularly in untreated hypogonadal men who, by nature of their T status, may be atrisk for CVD (118). The enzyme 5α-reductase catalyzes the formation of DHT from testosterone in certain tissues including the prostate gland, seminal vesicles, epididymides, skin, hair follicles, liver, and brain. As your body converts testosterone to DHT, if you have low levels of testosterone, you’ll have lower-than-normal levels of DHT as well. People with this condition have normal testes with normal to high testosterone levels — they just lack androgen receptors. one of the original "underground" methods used to falsify drug testing in sport, as DHT does not alter the ratio of testosterone to epistestosterone in an athlete's urinary steroid profile, a measurement that was once the basis of drug tests used to detect steroid use. It was not elucidated to be an endogenous substance until 1956, when it was shown to be formed from testosterone in rat liver homogenates. It was prepared via hydrogenation of testosterone, which had been discovered earlier that year. It is the derivative of testosterone in which the double bond between the C4 and C5 positions has been reduced or hydrogenated. DHT has been used as a performance enhancing drug, specifically as an alternative to testosterone, as it was once known to be capable of falsifying drug tests.|In rat studies, physiologicconcentrations of DHT 2 nmol/L (58 ng/dL) were shown to significantly inhibitadenosine 5′-diphosphate–induced platelet aggregation via direct interaction with ARs inplatelets. DHT has been shown to prevent macrophage foam cell formation in preclinical models.Ahmadi et al. demonstrated the presence of high-affinity ARs in avariety of types of macrophages and showed that DHT in pharmacologic concentrationsinhibits formation of IL-6 (109). However,most events clustered into the midnormal DHT range with few events at low or high DHTlevels, thus necessitating the use of a curvilinear model that resulted in wide confidenceintervals (CIs) (Fig. 5).|Even if your total testosterone levels are in a normal range, your free testosterone can still be low. The researchers also broke the data down into normal levels of free testosterone and bioavailable testosterone "Many studies that look at testosterone levels take an amount of people across these ages and test them for their T levels," says McDevitt. But determining normal testosterone levels by age? DHT is a potent androgen hormone that can cause serious harm to a developing fetus, including abnormal genital development. Dihydrotestosterone (DHT) is a hormone essential for male development and overall health. Traditionally known for producing "manly features," DHT causes facial and body hair to grow, the voice to deepen, and muscle tissue to develop. It also contributes to the growth and function of glands in the prostate and pelvis.2|At low circulating androgen levels, DHT binding is favoredover T but at higher relative T concentrations (e.g., eugonadal state),stabilization of the AR is driven by T more than DHT (20). Circulating DHT levels are of much lessimportance than T for optimizing the intracellular DHT concentrations due to the presence of arate-limiting enzyme, 5α-reductase (SRD5A; types I and II). This review on dihydrotestosterone (DHT) biology and the clinical implications of serum DHTconcentrations clarifies concepts that are of importance in clinical practice. In addition, the biological importance of DHT was not realized until the early 1960s, when it was found to be produced by 5α-reductase from circulating testosterone in target tissues like the prostate gland and seminal vesicles and was found to be more potent than testosterone in bioassays. Whereas 5α-reductase type 2 inhibitors achieve much higher reductions in circulating DHT production, MK-386 decreases circulating DHT levels by 20 to 30%. Long-term treatment with 5α-reductase inhibitors is also able to significantly reduce the overall risk of prostate cancer, although a simultaneous small increase in the risk of certain high-grade tumors has been observed.|DHT is significantly more potent than the other androgens; this is due to the high affinity of DHT to the androgen receptor, its slow dissociation, and its long half-life. This enzyme is present primarily at the target tissues where DHT exerts its actions, allowing the conversion of testosterone to DHT to occur only at these specific sites. This reduction step involves using NADPH to remove a double bond in the testosterone molecule.} However, as individual rates of conversion of testosterone to DHT vary tremendously, some healthcare professionals may recommend checking DHT levels during treatment. Currently, the use of TRT in men with hypogonadism is guided almost entirely by monitoring changes in testosterone levels; DHT is rarely considered when evaluating a patient’s therapeutic response to TRT. The average increase in DHT in studies of TRT is four to fivefold compared with baseline levels. In doing so, both testosterone levels and DHT are likely to increase. When men present with signs and symptoms of low testosterone levels, healthcare professionals often recommend testosterone replacement therapy (TRT). DHT is a more potent form of testosterone and can affect some tissues in a way that testosterone cannot.1 It is crucial in the sexual development of males, beginning early in prenatal life and continuing throughout puberty. This transformation primarily occurs in the testes, hair follicles, prostate, and adrenal glands.
